Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.69 |
| ▸ | CD69 | Q07108 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30104461 | 1.00 | BTK (0.69) | BTKCD69CYP3A4CYP2C9LCK | |
| SCHEMBL21791547 | 1.00 | BTK (0.69) | BTKCD69CYP3A4CYP2C9LCK | |
| SCHEMBL21791275 | 1.00 | BTK (0.69) | BTKCD69CYP3A4CYP2C9LCK | |
| SCHEMBL21791402 | 1.00 | BTK (0.69) | BTKCD69CYP3A4CYP2C9LCK | |
| SCHEMBL30104324 | 1.00 | BTK (0.69) | BTKCD69CYP3A4CYP2C9LCK | |
| SCHEMBL21791345 | 0.89 | BTK (0.69) | BTKCD69CYP3A4CYP2C9KCNH2 | |
| SCHEMBL30104319 | 0.89 | BTK (0.69) | BTKCD69CYP3A4CYP2C9KCNH2 | |
| SCHEMBL21791272 | 0.89 | BTK (0.69) | BTKCD69CYP3A4CYP2C9KCNH2 | |
| SCHEMBL21791522 | 0.89 | BTK (0.69) | BTKCD69CYP3A4CYP2C9KCNH2 | |
| SCHEMBL30104328 | 0.89 | BTK (0.69) | BTKCD69CYP3A4CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | MERCK PATENT GMBH (DE) | 2025-09-16 | — | — | US | claimed |
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | EMD Serono Research and Development Institute, Inc. | 2022-12-08 | — | — | US | claimed |
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | MERCK PATENT GMBH (DE) | 2025-09-16 | — | — | US | disclosed |
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | EMD Serono Research and Development Institute, Inc. | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | BTK, SYK, ABL1 | BTK 1/4885CD69 2403/4885CYP3A4 1946/4885 |
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, SYK, ABL1 | BTK 1/4885CD69 2403/4885CYP3A4 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.